|
The said tablets are bioequivalent to the reference listed drug (RLD), Mucinex Extended-Release Tablets, 600 mg and 1200 mg, of RB Health (US) LLC. Guaifenesin tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive. The company expects to launch the product immediately.
Commenting on the approval, Mark Saldanha, managing director of the company, said, “We are delighted to announce the approval, which further strengthens our growing Cough and Cold OTC portfolio in the US. We are confident in tapping the market opportunity of the product and remain committed to working diligently towards sustaining this momentum in the coming quarters.”
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.
On consolidated basis, the company's net profit jumped 15% to Rs 68.66 crore during the quarter as compared with Rs 59.72 crore posted in corresponding quarter last year. Net sales increased 15.3% year on year to Rs 500.03 crore in Q1 FY24 over Q1 FY23.
|